Suzanne Jansen, MSc, PharmD, ICON, says early-phase clinical success depends on flexible, simple formulations that support ...
New disease-modifying agents are being evaluated in the clinic that could change the course of treatment for Alzheimer’s disease patients. Regulated industries like pharmaceuticals, biotech, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results